Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
InMed Pharmaceuticals Inc. (INM) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cautionary Note Regarding Forward-Looking Information:"
09/29/2023 10-K Annual Report for the period ended June 30, 2023
09/29/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
07/24/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "InMed’ s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting Vancouver, BC – June 1, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid in InMed’ s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and ..."
05/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "InMed to Participate in Upcoming Virtual Investor Events Vancouver, BC – May 24, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the Company’ s executive team will be participating in the upcoming virtual investor events: Tribe Public Webinar Date: May 31, 2023 Time: 12:00 PM ET Registration: https://us06web.zoom.us/webinar/register/WN_6ZYkEADVSPOFd3g68IzQsw#/registration Eric A. Adams, CEO of InMed, and Jerry Griffin, VP, Sales and Marketing of BayMedica, will co-host a presentation event titled "Addressing The Increasing Demand For Rare Cannabinoids". Management will be available for a 5-10 minute Q&A session at the end of the presentation. Pleas..."
05/19/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cautionary Note Regarding Forward-Looking Information:"
05/16/2023 4 HSU ERIC C (Sr. VP, Pre-Clinical Res/Dev) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 152 options to buy @ $0
05/16/2023 4 MANCINI ALEXANDRA DIANE JANET (Sr VP, Clinical Reg Affairs) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 485 options to buy @ $0
05/16/2023 4 ADAMS ERIC A (President & CEO) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 1,818 options to buy @ $0
05/16/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update · Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 · 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary · Published a peer-reviewed study showing the anti-inflammatory potential of rare cannabinoids Vancouver, BC – May 15, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023. The Company’ s full financial statements and related MD&A for the third quarter ended March 31, 202..."
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/28/2023 8-K Quarterly results
03/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions"
03/09/2023 4 MANCINI ALEXANDRA DIANE JANET (Sr VP, Clinical Reg Affairs) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 61 options to buy @ $0
03/09/2023 4 HSU ERIC C (Sr. VP, Pre-Clinical Res/Dev) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 545 options to buy @ $0
03/09/2023 4 ADAMS ERIC A (President & CEO) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Unknown transaction of 545 options to buy @ $0
03/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "InMed to Participate in Upcoming Investor Events Vancouver, BC – March 6, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the Company’ s executive team will be participating in the upcoming virtual investor events throughout March 2023: Emerging Growth Conference Date: March 8, 2023 Time: 12:30 PM ET Registration: https://goto.webcasts.com/starthere.jsp?ei=1595542&tp_key=9ac5970e97&sti=inm InMed’ s CEO, Mr. Eric A. Adams, will present a corporate overview followed by a questions and answers session. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growt..."
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in INMED PHARMACEUTICALS, INC.
02/09/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cautionary Note Regarding Forward-Looking Information:"
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Grove Janet P (Director) has filed a Form 4 on InMed Pharmaceuticals Inc.
Txns: Granted 840 options to buy @ $1.78, valued at $1.5k
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy